⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20888942 | 0.79 | — | — | |
| SCHEMBL20888947 | 0.78 | — | — | |
| SCHEMBL20888989 | 0.77 | — | — | |
| SCHEMBL20888986 | 0.77 | — | — | |
| SCHEMBL20888940 | 0.75 | TNKS (0.32) | — | |
| SCHEMBL20888990 | 0.74 | — | — | |
| SCHEMBL20888985 | 0.72 | ACHE (0.31) | — | |
| SCHEMBL20888988 | 0.71 | — | — | |
| SCHEMBL20888939 | 0.68 | PGR (0.31) | — | |
| SCHEMBL20888978 | 0.66 | TNKS (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | ALDEYRA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230131929-A1 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | ALDEYRA THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210393527-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200038392-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE | ALDEYRA THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190105322-A1 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |